


WHAT IS CLAIMED IS:

1. A compound, or a pharmaceutically acceptable salt thereof, of Formula I:



I

wherein:

R¹, R², and R⁴ are independently selected from the group consisting of H and halide;

R³ is a 5-membered heteroaryl ring optionally substituted with from 1-4 R⁴²;

R⁵ is selected from the group consisting of unsubstituted -(C₁₋₉ alkyl), unsubstituted -(C₂₋₉ alkenyl), unsubstituted -(C₂₋₉ alkynyl), unsubstituted -(C₁₋₉ haloalkyl), -heteroaryl substituted with 1-4 R²⁶, a monocyclic -(C₁₋₄ alkylene)_pheterocyclyl optionally substituted with 1-10 R²⁷, a spirocyclic -heterocyclyl optionally substituted with 1-10 R²⁷, -(C₁₋₄ alkylene)_pcarbocyclyl optionally substituted with 1-12 R²⁸, and -aryl optionally substituted with 1-5 R²⁹; wherein each -(C₁₋₄ alkylene) is, independently, optionally substituted with a substituent as defined anywhere herein;

each R²⁶ is independently selected from the group consisting of halide, -OR³⁴, unsubstituted -(C₁₋₉ alkyl), unsubstituted -(C₂₋₉ alkenyl), unsubstituted -(C₂₋₉ alkynyl), unsubstituted -(C₁₋₉ haloalkyl), -C(C=O)N(R⁴¹)₂, -(C₁₋₄ alkylene)_pheterocyclyl optionally substituted with 1-10 R³⁵, and -O(C₁₋₄ alkylene)_pheterocyclyl optionally substituted with 1-10 R³⁶; wherein each -(C₁₋₄ alkylene) is, independently, optionally substituted with a substituent as defined anywhere herein;

each R²⁷ is independently selected from the group consisting of halide, unsubstituted -(C₁₋₉ alkyl), unsubstituted -(C₂₋₉ alkenyl), unsubstituted -(C₂₋₉ alkynyl), unsubstituted -(C₁₋₉ haloalkyl), -carbocyclyl optionally substituted with 1-12 R²⁸, and -aryl optionally substituted with 1-5 R⁴⁶;

each R²⁸ is independently selected from the group consisting of halide, -OR³⁸, unsubstituted -(C₁₋₉ alkyl), unsubstituted -(C₂₋₉ alkenyl), unsubstituted -(C₂₋₉ alkynyl), unsubstituted -(C₁₋₉ haloalkyl), and -(C₁₋₄ alkylene)_pheterocyclyl optionally substituted with 1-10 R³⁷; wherein -(C₁₋₄ alkylene) is, optionally substituted with a substituent as defined anywhere herein;

each R²⁹ is independently selected from the group consisting of halide, -OR³⁸, unsubstituted -(C₁₋₉ alkyl), unsubstituted -(C₂₋₉ alkenyl), unsubstituted -(C₂₋₉ alkynyl),

unsubstituted $-(C_{1-9} \text{ haloalkyl})$, $-(C_{1-4} \text{ alkylene})_p \text{ heterocyclyl}$ optionally substituted with 1-10 R^{39} , $-\text{NH heterocyclyl}$ optionally substituted with 1-10 R^{40} , and $-\text{O}(C_{1-4} \text{ alkylene})_p \text{ heterocyclyl}$ optionally substituted with 1-10 R^{40} ; wherein each $-(C_{1-4} \text{ alkylene})$ is, independently, optionally substituted with a substituent as defined anywhere herein;

each R^{34} is independently selected from the group consisting of unsubstituted $-(C_{1-4} \text{ alkyl})$, unsubstituted $-(C_{2-4} \text{ alkenyl})$, unsubstituted $-(C_{2-4} \text{ alkynyl})$, and unsubstituted $-(C_{1-4} \text{ haloalkyl})$;

each R^{35} is independently selected from the group consisting of unsubstituted $-(C_{1-4} \text{ alkyl})$, unsubstituted $-(C_{2-4} \text{ alkenyl})$, unsubstituted $-(C_{2-4} \text{ alkynyl})$, unsubstituted $-(C_{1-4} \text{ haloalkyl})$, halide, and $-\text{CN}$;

each R^{36} is independently selected from the group consisting of unsubstituted $-(C_{1-4} \text{ alkyl})$, unsubstituted $-(C_{2-4} \text{ alkenyl})$, unsubstituted $-(C_{2-4} \text{ alkynyl})$, unsubstituted $-(C_{1-4} \text{ haloalkyl})$, halide, and $-\text{CN}$;

each R^{37} is independently selected from the group consisting of unsubstituted $-(C_{1-4} \text{ alkyl})$, unsubstituted $-(C_{2-4} \text{ alkenyl})$, unsubstituted $-(C_{2-4} \text{ alkynyl})$, unsubstituted $-(C_{1-4} \text{ haloalkyl})$, halide, and $-\text{CN}$;

each R^{38} is independently selected from the group consisting of H, unsubstituted $-(C_{1-4} \text{ alkyl})$, unsubstituted $-(C_{2-4} \text{ alkenyl})$, unsubstituted $-(C_{2-4} \text{ alkynyl})$, and unsubstituted $-(C_{1-4} \text{ haloalkyl})$;

each R^{39} is independently selected from the group consisting of unsubstituted $-(C_{1-4} \text{ alkyl})$, unsubstituted $-(C_{2-4} \text{ alkenyl})$, unsubstituted $-(C_{2-4} \text{ alkynyl})$, unsubstituted $-(C_{1-4} \text{ haloalkyl})$, halide, and $-\text{CN}$;

each R^{40} is independently selected from the group consisting of unsubstituted $-(C_{1-4} \text{ alkyl})$, unsubstituted $-(C_{2-4} \text{ alkenyl})$, unsubstituted $-(C_{2-4} \text{ alkynyl})$, unsubstituted $-(C_{1-4} \text{ haloalkyl})$, halide, and $-\text{CN}$;

each R^{41} is independently selected from the group consisting of H and $-(C_{1-9} \text{ alkyl})$;

each R^{42} is independently selected from the group consisting of H, halide, unsubstituted $-(C_{1-9} \text{ alkyl})$, unsubstituted $-(C_{2-9} \text{ alkenyl})$, unsubstituted $-(C_{2-9} \text{ alkynyl})$, unsubstituted $-(C_{1-9} \text{ haloalkyl})$, $-(C_{1-4} \text{ alkylene})_p \text{ OH}$, $-(C_{1-4} \text{ alkylene})_p \text{ heterocyclyl}$ optionally substituted with 1-10 R^{43} , and $-\text{carbocyclyl}$ optionally substituted with 1-12 R^{44} ; wherein each $-(C_{1-4} \text{ alkylene})$ is, independently, optionally substituted with a substituent as defined anywhere herein;

alternatively, two adjacent R^{42} groups are taken together to form a ring which is selected from the group consisting of $-\text{heterocyclyl}$ optionally substituted with 1-10 R^{45} and $-\text{carbocyclyl}$ optionally substituted with 1-12 R^{46} ;

each R^{43} is independently selected from the group consisting of unsubstituted $-(C_{1-4} \text{ alkyl})$, unsubstituted $-(C_{2-4} \text{ alkenyl})$, unsubstituted $-(C_{2-4} \text{ alkynyl})$, unsubstituted $-(C_{1-4} \text{ haloalkyl})$, halide, and $-\text{CN}$;


each R^{44} is independently selected from the group consisting of unsubstituted $-(C_{1-4} \text{ alkyl})$, unsubstituted $-(C_{2-4} \text{ alkenyl})$, unsubstituted $-(C_{2-4} \text{ alkynyl})$, unsubstituted $-(C_{1-4} \text{ haloalkyl})$, halide, and $-\text{CN}$;

each R^{45} is independently selected from the group consisting of unsubstituted $-(C_{1-4} \text{ alkyl})$, unsubstituted $-(C_{2-4} \text{ alkenyl})$, unsubstituted $-(C_{2-4} \text{ alkynyl})$, unsubstituted $-(C_{1-4} \text{ haloalkyl})$, halide, and $-\text{CN}$;


each R^{46} is independently selected from the group consisting of unsubstituted $-(C_{1-4} \text{ alkyl})$, unsubstituted $-(C_{2-4} \text{ alkenyl})$, unsubstituted $-(C_{2-4} \text{ alkynyl})$, unsubstituted $-(C_{1-4} \text{ haloalkyl})$, halide, and $-\text{CN}$;

each p is independently 0 or 1; and

with the proviso that Formula I is not a structure selected from the group consisting of:




2. A compound, or a pharmaceutically acceptable salt thereof, of Formula I:



wherein:

R^1 , R^2 , and R^4 are independently selected from the group consisting of H and halide;

R^3 is selected from the group consisting of:



wherein each of R⁶-R²⁵ is, independently, a substituent as defined below or a single bond connecting R³ to the indazole ring; wherein only one of R⁶-R⁹ (when present) is a bond, only one of R¹⁰-R¹³ (when present) is a bond, only one of R¹⁴-R¹⁶ (when present) is a bond, only one of R¹⁷-R¹⁹ (when present) is a bond, only one of R²⁰-R²² is a bond, and only one of R²³-R²⁵ (when present) is a bond; for purposes of clarification, any one of the nitrogen atoms attached to R⁶, R¹⁰, R¹⁴, or R¹⁷ can serve as the point of attachment of R³ to the indazole ring; likewise, any one of the carbon atoms attached to R⁷, R⁸, R⁹, R¹¹, R¹², R¹³, R¹⁵, R¹⁶, R¹⁸, R¹⁹, R²⁰, R²¹, R²², R²³, R²⁴, R²⁵ can serve as the point of attachment of R³ to the indazole ring; accordingly:

when the nitrogen atom to which R⁶ is attached serves as the point of attachment of R³ to the indazole ring, then R⁶ is a single bond connecting R³ to the indazole ring;

when the carbon atom to which R⁷ is attached serves as the point of attachment of R³ to the indazole ring, then R⁷ is a single bond connecting R³ to the indazole ring;

when the carbon atom to which R⁸ is attached serves as the point of attachment of R³ to the indazole ring, then R⁸ is a single bond connecting R³ to the indazole ring;

when the carbon atom to which R⁹ is attached serves as the point of attachment of R³ to the indazole ring, then R⁹ is a single bond connecting R³ to the indazole ring;

when the nitrogen atom to which R¹⁰ is attached serves as the point of attachment of R³ to the indazole ring, then R¹⁰ is a single bond connecting R³ to the indazole ring;

when the carbon atom to which R¹¹ is attached serves as the point of attachment of R³ to the indazole ring, then R¹¹ is a single bond connecting R³ to the indazole ring;

when the carbon atom to which R¹² is attached serves as the point of attachment of R³ to the indazole ring, then R¹² is a single bond connecting R³ to the indazole ring;

when the carbon atom to which R¹³ is attached serves as the point of attachment of R³ to the indazole ring, then R¹³ is a single bond connecting R³ to the indazole ring;

when the nitrogen atom to which R¹⁴ is attached serves as the point of attachment of R³ to the indazole ring, then R¹⁴ is a single bond connecting R³ to the indazole ring;

when the carbon atom to which R¹⁵ is attached serves as the point of attachment of R³ to the indazole ring, then R¹⁵ is a single bond connecting R³ to the indazole ring;

when the carbon atom to which R¹⁶ is attached serves as the point of attachment of R³ to the indazole ring, then R¹⁶ is a single bond connecting R³ to the indazole ring;

when the nitrogen to which R¹⁷ is attached serves as the point of attachment of R³ to the indazole ring, then R¹⁷ is a single bond connecting R³ to the indazole ring;

when the carbon atom to which R¹⁸ is attached serves as the point of attachment of R³ to the indazole ring, then R¹⁸ is a single bond connecting R³ to the indazole ring;

when the carbon atom to which R¹⁹ is attached is instead attached to the indazole ring then R¹⁹ is a single bond connecting R³ to the indazole ring;

when the carbon atom to which R²⁰ is attached serves as the point of attachment of R³ to the indazole ring, then R²⁰ is a single bond connecting R³ to the indazole ring;

when the carbon atom to which R²¹ is attached serves as the point of attachment of R³ to the indazole ring, then R²¹ is a single bond connecting R³ to the indazole ring;

when the carbon atom to which R²² is attached serves as the point of attachment of R³ to the indazole ring, then R²² is a single bond connecting R³ to the indazole ring;

when the carbon atom to which R²³ is attached serves as the point of attachment of R³ to the indazole ring, then R²³ is a single bond connecting R³ to the indazole ring;

when the carbon atom to which R²⁴ is attached serves as the point of attachment of R³ to the indazole ring, then R²⁴ is a single bond connecting R³ to the indazole ring;

when the carbon to which R²⁵ is attached serves as the point of attachment of R³ to the indazole ring, then R²⁵ is a single bond connecting R³ to the indazole ring;

R⁵ is selected from the group consisting of unsubstituted -(C₁₋₉ alkyl), unsubstituted -(C₂₋₉ alkenyl), unsubstituted -(C₂₋₉ alkynyl), unsubstituted -(C₁₋₉ haloalkyl), -heteroaryl substituted with 1-4 R²⁶, a monocyclic -(C₁₋₄ alkylene)_pheterocyclyl optionally substituted with 1-10 R²⁷, a spirocyclic -heterocyclyl optionally substituted with 1-10 R²⁷, -(C₁₋₄ alkylene)_pcarbocyclyl optionally substituted with 1-12 R²⁸, and -aryl optionally substituted with 1-5 R²⁹, wherein each -(C₁₋₄ alkylene) is, independently, optionally substituted with a substituent as defined anywhere herein;

R⁶ is independently selected from the group consisting of H, unsubstituted -(C₁₋₉ alkyl), unsubstituted -(C₂₋₉ alkenyl), unsubstituted -(C₂₋₉ alkynyl), unsubstituted -(C₁₋₉ haloalkyl), -(C₁₋₄ alkylene)_pheterocyclyl optionally substituted with 1-10 R³⁰, and -carbocyclyl optionally substituted with 1-12 R³¹; wherein -(C₁₋₄ alkylene) is, optionally substituted with a substituent as defined anywhere herein;

R⁷, R⁸, and R⁹ are independently selected from the group consisting of H, halide, unsubstituted -(C₁₋₉ alkyl), unsubstituted -(C₂₋₉ alkenyl), unsubstituted -(C₂₋₉ alkynyl), unsubstituted -(C₁₋₉ haloalkyl), -(C₁₋₄ alkylene)_pOH, and -(C₁₋₄ alkylene)_pheterocyclyl optionally substituted with 1-10 R²⁷; wherein each -(C₁₋₄ alkylene) is, independently, optionally substituted with a substituent as defined anywhere herein;

alternatively, one of R⁶ and R⁷, R⁷ and R⁸, or R⁸ and R⁹ are taken together to form a ring which is selected from the group consisting of -heterocyclyl optionally substituted with 1-10 R³² and -carbocyclyl optionally substituted with 1-12 R³³;

R^{10} is independently selected from the group consisting of H, unsubstituted $-(C_{1-9} \text{ alkyl})$, unsubstituted $-(C_{2-9} \text{ alkenyl})$, unsubstituted $-(C_{2-9} \text{ alkynyl})$, unsubstituted $-(C_{1-9} \text{ haloalkyl})$, $-(C_{1-4} \text{ alkylene})_p$ heterocyclyl optionally substituted with 1-10 R^{30} , and $-\text{carbocyclyl}$ optionally substituted with 1-12 R^{31} ; wherein $-(C_{1-4} \text{ alkylene})$ is, optionally substituted with a substituent as defined anywhere herein;

R^{11} , R^{12} , and R^{13} are independently selected from the group consisting of H, halide, unsubstituted $-(C_{1-9} \text{ alkyl})$, unsubstituted $-(C_{2-9} \text{ alkenyl})$, unsubstituted $-(C_{2-9} \text{ alkynyl})$, and unsubstituted $-(C_{1-9} \text{ haloalkyl})$;

alternatively, one of R^{10} and R^{11} , R^{11} and R^{12} , or R^{13} and R^{10} are taken together to form a ring which is selected from the group consisting of $-\text{heterocyclyl}$ optionally substituted with 1-10 R^{32} and $-\text{carbocyclyl}$ optionally substituted with 1-12 R^{33} ;

R^{14} is independently selected from the group consisting of H, unsubstituted $-(C_{1-9} \text{ alkyl})$, unsubstituted $-(C_{2-9} \text{ alkenyl})$, unsubstituted $-(C_{2-9} \text{ alkynyl})$, unsubstituted $-(C_{1-9} \text{ haloalkyl})$, $-(C_{1-4} \text{ alkylene})_p$ heterocyclyl optionally substituted with 1-10 R^{30} , and $-\text{carbocyclyl}$ optionally substituted with 1-12 R^{31} ; wherein $-(C_{1-4} \text{ alkylene})$ is, optionally substituted with a substituent as defined anywhere herein;

R^{15} and R^{16} are independently selected from the group consisting of H, halide, unsubstituted $-(C_{1-9} \text{ alkyl})$, unsubstituted $-(C_{2-9} \text{ alkenyl})$, unsubstituted $-(C_{2-9} \text{ alkynyl})$, and unsubstituted $-(C_{1-9} \text{ haloalkyl})$;

alternatively, one of R^{14} and R^{15} or R^{16} and R^{14} are taken together to form a heterocyclyl optionally substituted with 1-10 R^{32} ;

R^{17} is independently selected from the group consisting of H, unsubstituted $-(C_{1-9} \text{ alkyl})$, unsubstituted $-(C_{2-9} \text{ alkenyl})$, unsubstituted $-(C_{2-9} \text{ alkynyl})$, unsubstituted $-(C_{1-9} \text{ haloalkyl})$, $-(C_{1-4} \text{ alkylene})_p$ heterocyclyl optionally substituted with 1-10 R^{30} , and $-\text{carbocyclyl}$ optionally substituted with 1-12 R^{31} ; wherein $-(C_{1-4} \text{ alkylene})$ is, optionally substituted with a substituent as defined anywhere herein;

R^{18} and R^{19} are independently selected from the group consisting of H, halide, unsubstituted $-(C_{1-9} \text{ alkyl})$, unsubstituted $-(C_{2-9} \text{ alkenyl})$, unsubstituted $-(C_{2-9} \text{ alkynyl})$, and unsubstituted $-(C_{1-9} \text{ haloalkyl})$;

alternatively, R^{18} and R^{19} are taken together to form a ring which is selected from the group consisting of $-\text{heterocyclyl}$ optionally substituted with 1-10 R^{32} and $-\text{carbocyclyl}$ optionally substituted with 1-12 R^{33} ;

R^{20} , R^{21} , and R^{22} are independently selected from the group consisting of H, halide, unsubstituted $-(C_{1-9} \text{ alkyl})$, unsubstituted $-(C_{2-9} \text{ alkenyl})$, unsubstituted $-(C_{2-9} \text{ alkynyl})$, and unsubstituted $-(C_{1-9} \text{ haloalkyl})$;

alternatively, one of R^{20} and R^{21} or R^{21} and R^{22} are taken together to form a ring which is selected from the group consisting of $-\text{heterocyclyl}$ optionally substituted with 1-10 R^{32} and $-\text{carbocyclyl}$ optionally substituted with 1-12 R^{33} ;

R^{23} , R^{24} , and R^{25} are independently selected from the group consisting of H, halide, unsubstituted $-(C_{1-9} \text{ alkyl})$, unsubstituted $-(C_{2-9} \text{ alkenyl})$, unsubstituted $-(C_{2-9} \text{ alkynyl})$, and unsubstituted $-(C_{1-9} \text{ haloalkyl})$;

alternatively, R^{23} and R^{24} are taken together to form a ring which is selected from the group consisting of $-\text{heterocyclyl}$ optionally substituted with 1-10 R^{32} and $-\text{carbocyclyl}$ optionally substituted with 1-12 R^{33} ;

each R^{26} is independently selected from the group consisting of halide, $-\text{OR}^{34}$, unsubstituted $-(C_{1-9} \text{ alkyl})$, unsubstituted $-(C_{2-9} \text{ alkenyl})$, unsubstituted $-(C_{2-9} \text{ alkynyl})$, unsubstituted $-(C_{1-9} \text{ haloalkyl})$, $-\text{C}(\text{C}=\text{O})\text{N}(\text{R}^{41})_2$, $-(C_{1-4} \text{ alkylene})_p\text{heterocyclyl}$ optionally substituted with 1-10 R^{35} , and $-\text{O}(C_{1-4} \text{ alkylene})_p\text{heterocyclyl}$ optionally substituted with 1-10 R^{36} ; wherein each $-(C_{1-4} \text{ alkylene})$ is, independently, optionally substituted with a substituent as defined anywhere herein;

each R^{27} is independently selected from the group consisting of halide, unsubstituted $-(C_{1-9} \text{ alkyl})$, unsubstituted $-(C_{2-9} \text{ alkenyl})$, unsubstituted $-(C_{2-9} \text{ alkynyl})$, unsubstituted $-(C_{1-9} \text{ haloalkyl})$, $-\text{carbocyclyl}$ optionally substituted with 1-12 R^{28} , and $-\text{aryl}$ optionally substituted with 1-5 R^{46} ;

each R^{28} is independently selected from the group consisting of halide, $-\text{OR}^{38}$, unsubstituted $-(C_{1-9} \text{ alkyl})$, unsubstituted $-(C_{2-9} \text{ alkenyl})$, unsubstituted $-(C_{2-9} \text{ alkynyl})$, unsubstituted $-(C_{1-9} \text{ haloalkyl})$, and $-(C_{1-4} \text{ alkylene})_p\text{heterocyclyl}$ optionally substituted with 1-10 R^{37} ; wherein $-(C_{1-4} \text{ alkylene})$ is, optionally substituted with a substituent as defined anywhere herein;

each R^{29} is independently selected from the group consisting of halide, $-\text{OR}^{38}$, unsubstituted $-(C_{1-9} \text{ alkyl})$, unsubstituted $-(C_{2-9} \text{ alkenyl})$, unsubstituted $-(C_{2-9} \text{ alkynyl})$, unsubstituted $-(C_{1-9} \text{ haloalkyl})$, $-(C_{1-4} \text{ alkylene})_p\text{heterocyclyl}$ optionally substituted with 1-10 R^{39} , $-\text{NHheterocyclyl}$ optionally substituted with 1-10 R^{40} , and $-\text{O}(C_{1-4} \text{ alkylene})_p\text{heterocyclyl}$ optionally substituted with 1-10 R^{40} ; wherein $-(C_{1-4} \text{ alkylene})$ is, optionally substituted with a substituent as defined anywhere herein;

each R³⁰ is independently selected from the group consisting of unsubstituted -(C₁₋₄ alkyl), unsubstituted -(C₂₋₄ alkenyl), unsubstituted -(C₂₋₄ alkynyl), unsubstituted -(C₁₋₄ haloalkyl), halide, and -CN;

each R³¹ is independently selected from the group consisting of unsubstituted -(C₁₋₄ alkyl), unsubstituted -(C₂₋₄ alkenyl), unsubstituted -(C₂₋₄ alkynyl), unsubstituted -(C₁₋₄ haloalkyl), halide, and -CN;

each R³² is independently selected from the group consisting of unsubstituted -(C₁₋₄ alkyl), unsubstituted -(C₂₋₄ alkenyl), unsubstituted -(C₂₋₄ alkynyl), unsubstituted -(C₁₋₄ haloalkyl), halide, and -CN;

each R³³ is independently selected from the group consisting of unsubstituted -(C₁₋₄ alkyl), unsubstituted -(C₂₋₄ alkenyl), unsubstituted -(C₂₋₄ alkynyl), unsubstituted -(C₁₋₄ haloalkyl), halide, and -CN;

each R³⁴ is independently selected from the group consisting of unsubstituted -(C₁₋₄ alkyl), unsubstituted -(C₂₋₄ alkenyl), unsubstituted -(C₂₋₄ alkynyl), and unsubstituted -(C₁₋₄ haloalkyl);

each R³⁵ is independently selected from the group consisting of unsubstituted -(C₁₋₄ alkyl), unsubstituted -(C₂₋₄ alkenyl), unsubstituted -(C₂₋₄ alkynyl), unsubstituted -(C₁₋₄ haloalkyl), halide, and -CN;

each R³⁶ is independently selected from the group consisting of unsubstituted -(C₁₋₄ alkyl), unsubstituted -(C₂₋₄ alkenyl), unsubstituted -(C₂₋₄ alkynyl), unsubstituted -(C₁₋₄ haloalkyl), halide, and -CN;

each R³⁷ is independently selected from the group consisting of unsubstituted -(C₁₋₄ alkyl), unsubstituted -(C₂₋₄ alkenyl), unsubstituted -(C₂₋₄ alkynyl), unsubstituted -(C₁₋₄ haloalkyl), halide, and -CN;

each R³⁸ is independently selected from the group consisting of H, unsubstituted -(C₁₋₄ alkyl), unsubstituted -(C₂₋₄ alkenyl), unsubstituted -(C₂₋₄ alkynyl), and unsubstituted -(C₁₋₄ haloalkyl);

each R³⁹ is independently selected from the group consisting of unsubstituted -(C₁₋₄ alkyl), unsubstituted -(C₂₋₄ alkenyl), unsubstituted -(C₂₋₄ alkynyl), unsubstituted -(C₁₋₄ haloalkyl), halide, and -CN;

each R⁴⁰ is independently selected from the group consisting of unsubstituted -(C₁₋₄ alkyl), unsubstituted -(C₂₋₄ alkenyl), unsubstituted -(C₂₋₄ alkynyl), unsubstituted -(C₁₋₄ haloalkyl), halide, and -CN;


each R⁴¹ is independently selected from the group consisting of H and -(C₁₋₉ alkyl);

each R^{46} is independently selected from the group consisting of unsubstituted $-(C_{1-4} \text{ alkyl})$, unsubstituted $-(C_{2-4} \text{ alkenyl})$, unsubstituted $-(C_{2-4} \text{ alkynyl})$, unsubstituted $-(C_{1-4} \text{ haloalkyl})$, halide, and $-\text{CN}$;


each X is O or S;


each p is independently 0 or 1; and


with the proviso that Formula I is not a structure selected from the group consisting of:



3. The compound according to any one of claims 1-2, wherein R^1 , R^2 and R^4 are H.
4. The compound according to any one of claims 1-2, wherein R^1 and R^4 are H, and R^2 is F.

5. The compound according to any one of claims 2-4, wherein R^3 is  ;
wherein

6. The compound according to any one of claims 2-4, wherein R^3 is .

7. The compound according to any one of claims 2-4, wherein R^3 is  and n is 1 to 3.

8. The compound according to any one of claims 2-6, wherein R^6 is selected from the group consisting of H, unsubstituted $-(C_{1-3} \text{ alkyl})$, unsubstituted $-(C_{1-2} \text{ haloalkyl})$, and $-(C_{3-4} \text{ carbocycl})$ optionally substituted with 1-2 R^{31} .




9. The compound according to any one of claims 2-6 and 8, wherein R^6 is selected from the group consisting of H, methyl, $-\text{CF}_3$, and cyclopropyl optionally substituted with 1-2 R^{31} .

10. The compound according to any one of claims 2-6, wherein R^7 is selected from the group consisting of H, halide, unsubstituted $-(C_{1-2} \text{ alkyl})$, and unsubstituted $-(C_{1-2} \text{ haloalkyl})$.

11. The compound according to any one of claims 2-6 and 10, wherein R^7 is selected from the group consisting of H, F, methyl, and $-CF_3$.

12. The compound according to any one of claims 2-4 and 7, wherein R^9 is selected from the group consisting of H and halide.

13. The compound according to any one of claims 2-4, 7, and 12, wherein R^9 is selected from the group consisting of H and F.



17. The compound according to any one of claims 2-4 and 14-15, wherein R^{10} is selected from the group consisting of H, unsubstituted $-(C_{1-3} \text{ alkyl})$, unsubstituted $-(C_{1-2} \text{ haloalkyl})$, and $-(C_{3-4} \text{ carbocyclyl})$ optionally substituted with 1-2 R^{31} .


18. The compound according to any one of claims 2-4, 14-15, and 17, wherein R^{10} is selected from the group consisting of H, methyl, $-CF_3$, and cyclopropyl optionally substituted with 1-2 R^{31} .

19. The compound according to any one of claims 2-4 and 14-16, wherein R^{12} is selected from the group consisting of H and halide.

20. The compound according to any one of claims 2-4, 14-16, and 19, wherein R^{12} is selected from the group consisting of H and F.

21. The compound according to any one of claims 2-4 and 14-15, wherein R^{13} is selected from the group consisting of H, halide, unsubstituted $-(C_{1-2} \text{ alkyl})$, and unsubstituted $-(C_{1-2} \text{ haloalkyl})$.

22. The compound according to any one of claims 2-4, 14-15, and 21, wherein R^{13} is selected from the group consisting of H, F, methyl, and $-CF_3$.




23. The compound according to any one of claims 2-4, wherein R^3 is

24. The compound according to any one of claims 2-4 and 23, wherein R^{24} is selected from the group consisting of H and halide.


25. The compound according to any one of claims 2-4 and 23-24, wherein R^{24} is selected from the group consisting of H and F.

26. The compound according to any one of claims 2-4 and 23, wherein R^{25} is selected from the group consisting of H, halide, unsubstituted $-(C_{1-2} \text{ alkyl})$, and unsubstituted $-(C_{1-2} \text{ haloalkyl})$.

27. The compound according to any one of claims 2-4, 23, and 26, wherein R^{25} is selected from the group consisting of H, F, methyl, and $-CF_3$.



28. The compound according to any one of claims 2-4, wherein R^3 is



29. The compound according to any one of claims 2-4, wherein R^3 is and n is 1 to 3.

30. The compound according to any one of claims 2-4 and 28, wherein R^{14} is selected from the group consisting of H, unsubstituted $-(C_{1-3} \text{ alkyl})$, unsubstituted $-(C_{1-2} \text{ haloalkyl})$, and $-(C_{3-4} \text{ carbocyclyl})$ optionally substituted with 1-2 R^{31} .

31. The compound according to any one of claims 2-4, 28, and 30, wherein R^{14} is selected from the group consisting of H, methyl, $-CF_3$, and cyclopropyl optionally substituted with 1-2 R^{31} .

32. The compound according to any one of claims 2-4 and 28, wherein R^{16} is selected from the group consisting of H, halide, unsubstituted $-(C_{1-2} \text{ alkyl})$, and unsubstituted $-(C_{1-2} \text{ haloalkyl})$.

33. The compound according to any one of claims 2-4, 28, and 32, wherein R^{16} is selected from the group consisting of H, F, methyl, and $-CF_3$.

34. The compound according to any one of claims 2-4, 28, and 30-31, wherein R^{31} is selected from the group consisting of halide, unsubstituted $-(C_{1-3} \text{ alkyl})$, and unsubstituted $-(C_{1-2} \text{ haloalkyl})$.

35. The compound according to any one of claims 2-4, 28, 30-31, and 34, wherein R^{31} is selected from the group consisting of F, methyl, and $-CF_3$.

36. The compound according to any one of claims 2-4, 16, and 29, wherein R^{32} is selected from the group consisting of H and unsubstituted $-(C_{1-2} \text{ alkyl})$.

37. The compound according to any one of claims 2-4, 16, 29, and 36, wherein R^{32} is selected from the group consisting of H and methyl.

38. The compound according to any one of claims 1-37, wherein R^5 is selected from the group consisting of unsubstituted $-(C_{1-9} \text{ alkyl})$, unsubstituted $-(C_{2-9} \text{ alkenyl})$, unsubstituted $-(C_{2-9} \text{ alkynyl})$, unsubstituted $-(C_{1-9} \text{ haloalkyl})$, $-\text{heteroaryl}$ substituted with 1-4 R^{26} , a 6-membered monocyclic $-(C_{1-4} \text{ alkylene})_p\text{heterocyclyl}$ optionally substituted with 1-10 R^{27} , a spirocyclic $-\text{heterocyclyl}$ optionally substituted with 1-10 R^{27} , $-(C_{1-4} \text{ alkylene})_p\text{carbocyclyl}$ optionally substituted with 1-12 R^{28} , and $-\text{aryl}$ optionally substituted with 1-5 R^{29} .

39. The compound according to any one of claims 1-38, wherein R^5 is selected from the group consisting of unsubstituted $-(C_{1-5} \text{ alkyl})$, unsubstituted $-(C_{1-4} \text{ haloalkyl})$, $-\text{heteroaryl}$ substituted with 1-2 R^{26} , a 6-membered monocyclic $-(C_{1-4} \text{ alkylene})_p\text{heterocyclyl}$ optionally substituted with 1-3 R^{27} , a spirocyclic $-\text{heterocyclyl}$ optionally substituted with 1-3 R^{27} , $-(C_{1-4} \text{ alkylene})_p\text{carbocyclyl}$ optionally substituted with 1-12 R^{28} , and $-\text{aryl}$ optionally substituted with 1-2 R^{29} .

40. The compound according to any one of claims 1-39, wherein R^5 is selected from the group consisting of unsubstituted $-(C_{1-4} \text{ alkyl})$ and unsubstituted $-(C_{1-3} \text{ fluoroalkyl})$.

41. The compound according to any one of claims 1-39, wherein R^5 is selected from the group consisting of $-\text{pyridinyl}$ substituted with 1 R^{26} and $-\text{thiazolyl}$ substituted with 1 R^{26} .


42. The compound according to any one of claims 1-39, wherein R^5 is selected from the group consisting of a 6-membered monocyclic $-\text{heterocyclyl}$ optionally substituted with 1-2 R^{27} and a spirocyclic $-\text{heterocyclyl}$ optionally substituted with 1 R^{27} .

43. The compound according to any one of claims 1-39, wherein R^5 is selected from the group consisting of -carbocyclyl optionally substituted with 1-2 R^{28} and $-CH_2$ carbocyclyl optionally substituted with 1-2 R^{28} .

44. The compound according to any one of claims 1-39, wherein R^5 is -phenyl substituted with 1-2 R^{29} .

45. The compound according to any one of claims 1-39 and 41, wherein R^{26} is selected from the group consisting of halide, $-O(C_{1-2}$ fluoroalkyl), unsubstituted $-(C_{1-3}$ alkyl), unsubstituted $-(C_{1-3}$ fluoroalkyl), -heterocyclyl optionally substituted with 1-2 R^{35} , and $-O$ heterocyclyl optionally substituted with 1-2 R^{36} .

46. The compound according to any one of claims 1-39, 41, and 45, wherein R^{26} is




47. The compound according to any one of claims 1-39 and 42, wherein R^{27} is selected from the group consisting of halide, unsubstituted $-(C_{1-4}$ alkyl), unsubstituted $-(C_{1-4}$ haloalkyl), -carbocyclyl optionally substituted with 1-2 R^{28} , and -aryl optionally substituted with 1-2 R^{46} .

48. The compound according to any one of claims 1-39, 42, and 47, wherein R^{27} is selected from the group consisting of F, unsubstituted $-(C_{1-4}$ alkyl), unsubstituted $-(C_{1-4}$ fluoroalkyl), -cyclopropyl, and phenyl.


49. The compound according to any one of claims 1-39 and 43, wherein R^{28} is selected from the group consisting of halide, $-O(C_{1-3}$ alkyl), unsubstituted $-(C_{1-3}$ alkyl), unsubstituted $-(C_{1-3}$ haloalkyl), and $-CH_2$ heterocyclyl optionally substituted with 1-2 R^{37} .

50. The compound according to any one of claims 1-39, 43, and 49, wherein R^{28} is





51. The compound according to any one of claims 1-39 and 44, wherein R^{29} is independently selected from the group consisting of halide, $-OH$, $-O(C_{1-3}$ haloalkyl), unsubstituted $-(C_{1-3}$ alkyl), unsubstituted $-(C_{1-3}$ haloalkyl), -heterocyclyl optionally substituted with 1-2 R^{39} , $-CH_2$ heterocyclyl optionally substituted with 1-2 R^{39} , $-NH$ heterocyclyl optionally substituted with 1-2 R^{40} , and $-O(C_{1-2}$ alkylene)_pheterocyclyl optionally substituted with 1-2 R^{40} .


52. The compound according to any one of claims 1-39, 44, and 51, wherein R^{29} is independently selected from the group consisting of F, $-OH$, $-OCHF_2$, $-OCF_3$, methyl, $-CF_3$,




53. The compound according to any one of claims 1-2, wherein the compound of Formula I is selected from the group consisting of:




















a pharmaceutically acceptable salt thereof.

54. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to any one of claims 1-53, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

55. A method of treating a disorder or disease in a patient, wherein the disorder or disease is selected from the group consisting of: tendinopathy, dermatitis, psoriasis, morphea, ichthyosis, Raynaud's syndrome, Darier's disease, cancer, pulmonary fibrosis, idiopathic pulmonary fibrosis (IPF), degenerative disc disease, bone/osteoporotic fractures, a bone or cartilage disease, a neurological disorder, osteoarthritis, lung disease, a fibrotic disorder, the method comprising administering to the patient a therapeutically effective amount of a compound according to any one of claims 1-53, or a pharmaceutically acceptable salt thereof.

56. The method of claim 55, wherein the disorder or disease is cancer.

57. The method of claim 55, wherein the disorder or disease is tendinopathy.

58. The method of claim 55, wherein the disorder or disease is dermatitis.

59. The method of claim 55, wherein the disorder or disease is psoriasis.

60. The method of claim 55, wherein the disorder or disease is morphea.

61. The method of claim 55, wherein the disorder or disease is ichthyosis.

62. The method of claim 55, wherein the disorder or disease is Raynaud's syndrome.

63. The method of claim 55, wherein the disorder or disease is Darier's disease.

64. The method of claim 55, wherein the disorder or disease is pulmonary fibrosis.

65. The method of claim 55, wherein the disorder or disease is idiopathic pulmonary fibrosis (IPF).

66. The method of claim 55, wherein the disorder or disease is lung disease.

67. The method of claim 55, wherein the disorder or disease is degenerative disc disease.

68. The method of claim 55, wherein the disorder or disease is a bone/osteoporotic fracture.

69. The method of claim 55, wherein the disorder or disease is a bone or cartilage disease.

70. The method of claim 55, wherein the disorder or disease is osteoarthritis.

71. The method of claim 55, wherein the disorder or disease is a neurological disorder.

72. The method according to any one of claims 55-71, wherein the patient is a human.

73. The method according to any one of claims 55-56, wherein the cancer is selected from the group consisting of: hepatocellular carcinoma, colon cancer, breast cancer, pancreatic cancer, chronic myeloid leukemia (CML), chronic myelomonocytic leukemia, chronic lymphocytic leukemia (CLL), acute myeloid leukemia, acute lymphocytic leukemia, Hodgkin lymphoma, lymphoma, sarcoma, and ovarian cancer.

74. The method according to any one of claims 55-56, wherein the cancer is selected from the group consisting of: lung cancer - non-small cell, lung cancer - small cell, multiple

myeloma, nasopharyngeal cancer, neuroblastoma, osteosarcoma, penile cancer, pituitary tumors, prostate cancer, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, skin cancer - basal and squamous cell, skin cancer – melanoma, small intestine cancer, stomach cancers, testicular cancer, thymus cancer, thyroid cancer, uterine sarcoma, vaginal cancer, vulvar cancer, laryngeal or hypopharyngeal cancer, kidney cancer, Kaposi sarcoma, gestational trophoblastic disease, gastrointestinal stromal tumor, gastrointestinal carcinoid tumor, gallbladder cancer, eye cancer (melanoma and lymphoma), Ewing tumor, esophagus cancer, endometrial cancer, colorectal cancer, cervical cancer, brain or spinal cord tumor, bone metastasis, bone cancer, bladder cancer, bile duct cancer, anal cancer, and adrenal cortical cancer.

75. The method according to any one of claims 55 and 71, wherein the disorder or disease is a neurological disorder, wherein the neurological condition/disorder/disease is selected from the group consisting of: frontotemporal dementias, dementia with lewy bodies, prion diseases, Parkinson's disease, Huntington's disease, progressive supranuclear palsy, corticobasal degeneration, multiple system atrophy, amyotrophic lateral sclerosis (ALS), inclusion body myositis, autism, degenerative myopathies, diabetic neuropathy, other metabolic neuropathies, endocrine neuropathies, orthostatic hypotension, multiple sclerosis and Charcot-Marie-Tooth disease.

76. The method according to any one of claims 55, 71 and 75, wherein the disorder or disease is a neurological disorder associated with tau protein, amyloid, or alpha-synuclein pathology.

77. The method according to any one of claims 55, 71 and 75-76, wherein the disorder or disease is selected from the group consisting of: Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Down Syndrome, Frontotemporal Dementia with Parkinsonism-17 (FTDP-17), Lewy body dementia, Parkinson's Disease, Pick's Disease, and additional diseases with pronounced neurodegeneration such as Autism, Dementia, Epilepsy, Huntington's Disease, Multiple Sclerosis; diseases and disorders associated with acquired brain injury such as Chronic Traumatic Encephalopathy, Traumatic Brain Injury, Tumor, and Stroke.

78. The method of claim 55, wherein the disorder or disease is a fibrotic disorder, wherein the fibrotic disorder is selected from the group consisting of: skin fibrosis; scleroderma; progressive systemic fibrosis; lung fibrosis; muscle fibrosis; kidney fibrosis; glomerulosclerosis; glomerulonephritis; hypertrophic scar formation; uterine fibrosis; renal fibrosis; cirrhosis of the liver, liver fibrosis; adhesions; chronic obstructive pulmonary disease; fibrosis following myocardial infarction; pulmonary fibrosis; fibrosis and scarring associated with diffuse/interstitial

lung disease; central nervous system fibrosis; fibrosis associated with proliferative vitreoretinopathy (PVR); restenosis; endometriosis; ischemic disease, and radiation fibrosis.

79. The method of claim 78, wherein the fibrotic disorder is scleroderma.

80. The method according to any one of claims 55-79, wherein the compound inhibits one or more proteins in the Wnt pathway.

81. The method according to any one of claims 55-79, wherein the compound inhibits signaling induced by one or more Wnt proteins.

82. The method according to claim 81, wherein the Wnt proteins are selected from the group consisting of: WNT1, WNT2, WNT2B, WNT3, WNT3A, WNT4, WNT5A, WNT5B, WNT6, WNT7A, WNT7B, WNT8A, WNT8B, WNT9A, WNT9B, WNT10A, WNT10B, WNT11, and WNT16.

83. The method according to any one of claims 55-79, wherein the compound inhibits DYRK1A.

84. The method according to any one of claims 55-79, wherein the compound inhibits GSK3 β .

85. The method according to any one of claims 55-79, wherein the compound inhibits a kinase activity.

86. A method of preventing or reducing angiogenesis in a patient, the method comprising administering to the patient a therapeutically effective amount of a compound according to any one of claims 1-53, or a pharmaceutically acceptable salt thereof.